Market Overview

Globus Medical Stands On The Brink Of Inflection; Leerink Upgrades

Benzinga's Biotech Pulse: Pfizer's Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial
The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs
Bulletproof Investing Performance Update: Week 46 (Seeking Alpha)

Considering Globus Medical Inc (NYSE: GMED) on the verge of significant revenue growth acceleration, Leerink Swann upgraded the musculoskeletal medical device company to Outperform and increased its price target from $29 to $40.

The firm has been anticipating the ratings change since it downgraded Globus Medical in July.

“We had been of the mindset there would eventually be an organic growth acceleration pick-up later in 2017 and that the company would likely be worth re-visiting in mid-2017,” analysts Richard Newitter and Ravi Misra wrote in a note.

Now, Globus Medical is nearing its predicted inflection point, and Leerink foresees a shift from negative to positive growth in the first half of 2017. Additionally, it expects about 14 percent year-over-year revenue growth through the second quarter of 2018.

Source Of Strength

The company is expected to gain momentum from four factors: recent recruitment of experienced representatives, increasing profits from junior rep training programs, new product launches and new revenue from the robotics and trauma pipeline.

The latter is expected to generate $11 million in the second half of 2017 and another $35 million in 2018.

Reading The Numbers

While Globus Medical has already rebounded (nearly 43 percent) from 2016 lows and rests at an all-time high, Leerink still sees room to inch higher. Analysts noted that the present valuation doesn't well reflect sales growth acceleration and above-average profitability.

Because Globus Medical’s stock and multiple valuation are strongly correlated with periods of re-accelerated growth, it appears that the company’s multiple could expand from a discount to a premium.

“We expect GMED is about to generate its strongest growth rebound yet over the next 12 to 14 months,” Newitter and Misra wrote.

Risks to the thesis include a slowdown in the spine market and a delay in the company’s robotics and trauma pipeline.

Globus Medical was trading up 3 percent at $30.71 at time of publication.

Latest Ratings for GMED

Sep 2018Morgan StanleyMaintainsOverweightOverweight
Aug 2018Morgan StanleyMaintainsOverweightOverweight
Jun 2018Cantor FitzgeraldInitiates Coverage OnOverweight

View More Analyst Ratings for GMED
View the Latest Analyst Ratings

Posted-In: Leerink Swann Medtech Ravi Misra Richard NewitterAnalyst Color Upgrades Price Target Analyst Ratings


Related Articles (GMED)

View Comments and Join the Discussion!

Latest Ratings

ETTXWedbushInitiates Coverage On19.0
HRZNKeefe Bruyette & WoodsDowngrades10.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Prolonged Correction In ON Semiconductor Prompts Vetr To Issue Upgrade

Only In New York: 'Charging Bull' Sculptor Hints Lawsuit Against 'Fearless Girl'